Tests to predict the responsiveness of patients with cancer chemotherapy treatment options

摘要

Method of predicting whether a patient with breast cancer present a beneficial response to chemotherapy, comprising: measuring an expression level of DDR1, or its expression product in a tumor sample obtained from the patient; use the expression level to determine a likelihood of beneficial response to treatment comprising a taxane, wherein the expression of DDR1 is positively correlated with an increased chance of beneficial response to treatment comprising a taxane, and generate a report that includes information based on the likelihood of a beneficial response to chemotherapy including a taxane.